C-HEP final book by Strata Media Group

C-HEP

THE 3RD WORLD CONGRESS ON

THE 2ND WORLD CONGRESS ON

CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITIS

ISTANBUL, 2013

Berlin, Germany • October 18-20, 2012

See you there!

PROGRAM

www.comtecmed.com/chep • chep@comtecmed.com

C-HEP cover RUN.indd 1

4/10/12 15:18:51

C-HEP Advert A4_Layout 1 13/09/2012 10:25 Page 1

THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITIS BERLIN, GERMANY • OCTOBER 18-20, 2012

C-HEP PARTICIPANTS CAME FROM… 37 Countries (as of October 2, 2012)

You are cordially invited to attend the satellite symposium at the 2nd World Congress on Controversies in the Management of Viral Hepatitis (C-Hep)

DAAs: Raising Standards in Patient Care Chair: Thomas Berg, Germany on Thursday 18 October 2012, 18:00–19:15 Hall A, Leonardo Royal Hotel Berlin, Germany

With the support of Janssen Pharmaceutical Companies of Johnson & Johnson in EMEA

Janssen Pharmaceutica NV

C-HEP cover RUN.indd 2

EMEA/HEP/0812/0804

Azerbaijan

Bahrain

Belgium

Canada

Czech Republic

Denmark

Estonia

Finland

France

Georgia

Germany

Greece

Hungary

India

Israel

Italy

Japan

Lithuania

Luxembourg

Malta

Nigeria

Norway

Poland

Portugal

Qatar

Romania

Russia

Serbia

Slovak Republic

Spain

Sweden

Switzerland

Thailand

Turkey

USA

Vietnam

4/10/12 15:18:54

C-HEP THE 2ND WORLD CONGRESS ON

CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITIS

Berlin, Germany • October 18-20, 2012

PROGRAM

www.comtecmed.com/chep • chep@comtecmed.com

01-26-C-HEP-part 1.indd 3

4/10/12 15:07:43

01-26-C-HEP-part 1.indd 4

4/10/12 15:07:48

THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITIS Berlin, Germany • October 18-20, 2012

TIMETABLE Thursday, October 18, 2012 Hall A 14:00-16:00

PLENARY SESSION 1 Hepatitis C – Addressing the Challenge

16:00-17:30

Pipeline Showcase New Drugs on the Horizon

17:30-18:00

Coffee Break and Poster Exhibition

18:00-19:15 Satellite Symposium JANSSEN PHARMACEUTICALS DAAs: Raising standards in patient care 19:15-20:30

Welcome Reception Sponsored by Abbott

Friday, October 19, 2012 09:00-11:00

Hall A Hall B PLENARY SESSION 2 HCV Direct Acting Antivirals: How have the treatment paradigms changed

11:00-11:30 11:30-12:15

Coffee Break

SESSION 3 Do we need to know genetic factors such as IL28B for treatment decision making?

12:15-13:00

SESSION 4 HCV therapy is for specialists only? Lunch

13:00-14:15

Satellite Symposium MERCK SHARP & DOHME Successful HCV Treatment in the Real World: Lessons From Clinical Practice

14:15-15:45

PLENARY SESSION 5 Hepatitis: State of the Art Clinical Care

15:45-16:15 16:15-17:00

Coffee Break and Poster Prize Ceremony

SESSION 6 Should patients wait for DAA combination therapy?

SESSION 7 Resistance to HCV Protease Inhibitors: Game over?

17:00-17:30 SESSION 8 SESSION 9 Interactive Case Session: How to treat HCV Interactive Case Session: How to treat HCV in relapse after Liver Transplant? HIV coinfection Supported by an unrestricted grant from Boehringer Ingelheim

Saturday, October 20, 2012 Hall A 08:30-10:30

PLENARY SESSION 10 HBV therapy in 2012

10:30-11:00

Coffee Break

11:00-11:45

PLENARY SESSION 11 Interactive Case Session and Discussion: The challenging hepatitis B Case Supported by an unrestricted grant from Gilead Sciences Europe Ltd.

11:45-12:45

PLENARY SESSION 12 HCV – Looking to the Future

12:45-13:00

Farewell Toast

[ 5 ]

01-26-C-HEP-part 1.indd 5

4/10/12 15:07:50

T:210 mm S:190 mm

Value through Innovation

Boehringer Ingelheim Is Advancing

NEXTďż˝GENERATION AGENTS

T:297 mm S:277 mm

Aiming to Deliver Improved Treatments Our rigorous HCVersoTM clinical trial program is designed to answer the difficult questions in HCV: how to reduce the burden of treatment and cure more patients.

Ultimately, Eliminating the Need for Interferon With interferon-free treatment regimens, we strive to reach our goal of delivering a more convenient cure for patients. The novel clinical investigational compounds may offer the potential for new therapies with greater efficacy, improved tolerability, and shorter treatment duration compared with current approaches in HCV treatment. If you would like to learn more about Boehringer Ingelheim, visit us at www.boehringer-ingelheim.com.

01-26-C-HEP-part 1.indd 6

4/10/12 15:07:51

THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITIS Berlin, Germany â&#x20AC;˘ October 18-20, 2012

TABLE OF CONTENTS Welcome Note

B:303 mm T:297 mm S:277 mm

Committees

Faculty

CME Accreditation

Sponsors

Acknowledgements

Exhibition Floorplan

Partners

Endorsements

General Information

Scientific Program

Thursday, October 18, 2012

Friday, October 19, 2012

Saturday, October 20, 2012

Index

[ 7 ]

01-26-C-HEP-part 1.indd 7

4/10/12 15:08:01

THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITIS Berlin, Germany • October 18-20, 2012

[ 8 ]

01-26-C-HEP-part 1.indd 8

4/10/12 15:08:09

THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITIS Berlin, Germany • October 18-20, 2012

DEAR FRIENDS AND COLLEAGUES, Following the success of the 1st World Congress on Controversies in the Management of Viral Hepatitis (C-Hep), we are very pleased to have you here in Berlin to participate in the 2nd C-Hep Congress. The large attendance and enthusiastic feedback of the 1st Congress held last May in Barcelona highlighted the need for such a meeting focusing on the needs of the busy clinician caring for HCV and HBV infected patients. The C-Hep Congress attempts to summarize all the key new data recently presented – and how it might be implemented in routine care of Hepatitis B and C patients. Overviews, state of the art lectures and controversial debates with the outstanding faculty of prominent world leaders presenting both pro and con positions challenge and explore the optimal treatment for patients, including the appropriate use of new drugs. This educational Congress focuses on clinical practices in Viral Hepatitis and benefits not only Hepatologists and Infectious Diseases specialist, but also general practitioners, internists and primary care physicians with a desire to gain knowledge in these exciting advances. The format includes a significant allocation of time for interactive debates and questions from the audience to each panel of experts. Participants are encouraged to take an active role in the discussions with faculty members which follow each debate, in a unique and open environment. We look forward to having you participate during the 2nd C-Hep Congress in the lovely city of Berlin.

Sincerely, Jürgen Rockstroh MD Jonathan M. Schapiro MD Germany Israel Co-Chairpersons

[ 9 ]

01-26-C-HEP-part 1.indd 9

4/10/12 15:08:14

THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITIS Berlin, Germany • October 18-20, 2012

Co-Chairpersons

Jürgen Rockstroh, MD Germany

Jonathan M. Schapiro, MD Israel

HCV PROGRAM DIRECTOR

Stefan Zeuzem, Germany Klinikum der J.W. Goethe-Universitat, Med. Klinik 1

HBV PROGRAM DIRECTOR

Fabien Zoulim, France INSERM U1052, Lyon University, Hepatology Department, Hospices Civils de Lyon

[ 10 ]

01-26-C-HEP-part 1.indd 10

4/10/12 15:08:17

THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITIS Berlin, Germany • October 18-20, 2012

SCIENTIFIC COMMITTEE David Back, UK

Jean Michel Pawlotsky, France

Department of Molecular and Clinical Pharmacology, University of Liverpool

Department of Virology, Henri Mondor Hospital, University of Paris

Thomas Berg, Germany

Carlo Perno, Italy

Head of the Division of Hepatology, Department of Internal Medicine, Clinic of Gastroenterology and Rheumatology, University Hospital Leipzig

Tor Vergata University Hospital, Rome

Marion Peters, USA

Raffaele Bruno, Italy Department of Infectious Diseases, Hepatology Outpatients Unit, University of Pavia Fondazione IRCCS, Policlinico San Matteo, Pavia

Chief of Hepatology Research, Division of Gastroenterology, University of California, San Francisco

Jörg Petersen, Germany Liver Unit, IFI Institute for Interdisciplinary Medicine, Asklepios Klinik St. Georg, Hamburg

Maria Buti, Spain Hospital Valle Hebron, Barcelona

Massimo Puoti, Italy Department of Infectious Diseases. AO Ospedale Niguarda Ca’ Granda, Milan

Bonaventura Clotet, Spain HIV Unit and irsicaixa Foundation, University Hospital “Germans Trias i Pujol”, Badalona, Catalonia

Vicente Soriano, Spain

Douglas T. Dieterich, USA

Hospital Carlos III, Madrid

Professor of Medicine, Mount Sinai School of Medicine, New York

Mark R. Thursz, UK Geoffrey Dusheiko, UK

Professor of Hepatology, Imperial College, London

UCL Centre for Hepatology, University College London Medical School, and Royal Free Hospital, London

Hans L. Tillmann, USA

Rafael Esteban, Spain

Duke Clinical Research Institute

Vall d’Hebron University Hospital

Heiner Wedemeyer, Germany

Michael P. Manns, Germany

Hannover Medical School

Hannover Medical School, Department of Gastroenterology, Hepatology and Endocrinology

Stefan Mauss, Germany Center for HIV and Hepatogastroenterology, Duesseldorf

[ 11 ]

01-26-C-HEP-part 1.indd 11

4/10/12 15:08:26

THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITIS Berlin, Germany • October 18-20, 2012

FACULTY Matthew Albert, France

Patrick Ingiliz, Germany

Immunobiology of Dendritic Cells, Institut Pasteur, Paris

Medical Center for Infectious Diseases, Berlin

David Back, UK

Karine Lacombe, France

Department of Molecular and Clinical Pharmacology, University of Liverpool

Infectious and Tropical Diseases Department, Saint-Antoine Hospital (APHP) & INSERM, UMR-S707 Paris

Thomas Berg, Germany

Christian M. Lange, Germany

Head of the Division of Hepatology, Department of Internal Medicine, Clinic of Gastroenterology and Rheumatology, University Hospital Leipzig

Department of Internal Medicine 1, Johann Wolfgang Goethe University Hospital Frankfurt a. M.

Michel Biermer, Germany

INSERM, UMR-S707 & Hopital SaintAntoine, Paris

Maud Lemoine, France

Hepatologie und Gastroenterologie, University Hospital Leipzig

Michael P. Manns, Germany

Raffaele Bruno, Italy Department of Infectious Diseases, Hepatology Outpatients Unit, University of Pavia Fondazione IRCCS, Policlinico San Matteo, Pavia

Hannover Medical School, Department of Gastroenterology, Hepatology and Endocrinology

Stefan Mauss, Germany Center for HIV and Hepatogastroenterology, Duesseldorf

Maria Buti, Spain Hospital Valle Hebron, Barcelona

Marie-Louise Michel, France Pasteur Institut and Inserm U845, Paris

Geoffrey Dusheiko, UK UCL Centre for Hepatology, University College London Medical School, and Royal Free Hospital, London

Mark Nelson, UK Chelsea and Westminster Hospital, London

Rafael Esteban, Spain Vall d’Hebron University Hospital

Claus Niederau, Germany Director of the Department of Medicine, Katholische Kliniken Oberhausen, St. Josef- and St. Marienhospital, Academic Teaching Hospital of the University of Duisburg-Essen

Graham Foster, UK Professor of Hepatology, Queen Marys University of London

Christoph Hezode, France

Jean Michel Pawlotsky, France

Hôpital Henri-Mondor, Université ParisEst Créteil

Department of Virology, Henri Mondor Hospital, University of Paris

[ 12 ]

01-26-C-HEP-part 1.indd 12

4/10/12 15:08:39

THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITIS Berlin, Germany • October 18-20, 2012

FACULTY Marion Peters, USA

Vicente Soriano, Spain

Chief of Hepatology Research, Division of Gastroenterology, University of California, San Francisco

Hospital Carlos III, Madrid

Jörg Petersen, Germany

Ulrich Spengler, Germany

Liver Unit, IFI Institute, Asklepios Klinik St. Georg, Hamburg

Professor for Hepatotology, Department of Medicine, University Hospital Bonn

Stanislas Pol, France

Mark R. Thursz, UK

Stanislas Pol, France Université Paris Descartes & Hôpital Cochin, Paris

Professor of Hepatology, Imperial College, London

Massimo Puoti, Italy

Florian van Bömmel, Germany

Department of Infectious Diseases. AO Ospedale Niguarda Ca’ Granda, Milan

Department of Hepatology and Gastroenterology, University Hospital Leipzig

Jürgen Rockstroh, Germany

Heiner Wedemeyer, Germany

Department of Medicine, University Hospital Bonn

Hannover Medical School

Christoph Sarrazin, Germany

Stefan Zeuzem, Germany

Professor of Medicine, Department of Internal Medicine 1, J.W. GoetheUniversity Hospital, Frankfurt

Klinikum der J.W. Goethe-Universitat, Med. Klinik 1

Jonathan M. Schapiro, Israel

Fabien Zoulim, France

National Hemophilia Center, Sheba Medical Center

INSERM U1052, Lyon University, Hepatology Department, Hospices Civils de Lyon

Eckart Schott, Germany Department of Hepatology and Gastroenterology, Charité Universitätsmedizin Berlin

[ 13 ]

01-26-C-HEP-part 1.indd 13

4/10/12 15:08:52

01-26-C-HEP-part 1.indd 14

4/10/12 15:09:00

THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITIS Berlin, Germany • October 18-20, 2012

CME ACCREDITATION

The 2nd World Congress on Controversies in the Management of Viral Hepatitis (C-Hep) is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net. The 2nd World Congress on Controversies in the Management of Viral Hepatitis (C-Hep) is designated for a maximum of (or ‘for up to’) 11 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.amaassn.org/go/internationalcme. Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

[ 15 ]

01-26-C-HEP-part 1.indd 15

4/10/12 15:09:04

THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITIS Berlin, Germany • October 18-20, 2012

SPONSORS The C-Hep Congress gratefully acknowledges the generous support of the Sponosrs PLATINUM

GOLD

SILVER

SPONSORS

[ 16 ]

01-26-C-HEP-part 1.indd 16

4/10/12 15:09:05

THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITIS Berlin, Germany • October 18-20, 2012

Acknowledgements PLATINUM

Janssen Pharmaceutical Companies of Johnson & Johnson 50-100 Holmers Farm Way, High Wycombe, HP12 4DP United Kingdom Contact: Sarah Walker Tel: +44 7876.217.895 Fax: +44 131.301.0054 Email: swalker5@its.jnj.com Website: www.stop-hepatitis-c.info

Merck Sharp & Dohme (MSD) One Merck Drive PO Box 100 Whitehouse Station, New Jersey 08889

Janssen Pharmaceutical Companies of Johnson & Johnson Janssen is committed to improving the lives of people impacted by hepatitis C worldwide by establishing innovative treatment regimens that significantly improve patient outcomes. Our strong heritage in virology will help us to become a leader in hepatitis C through the development of products that redefine the standard of care. In 2011, we launched INCIVO® (telaprevir), a protease inhibitor co-developed with Vertex Pharmaceuticals Inc, for patients suffering from genotype 1 chronic HCV. Visit: www.stophepatitis-c.info

Today’s MSD is a global healthcare leader working to help the world be well. MSD is known as Merck in the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information visit www.merck.com and connect with us on Twitter, Facebook and YouTube.

[ 17 ]

01-26-C-HEP-part 1.indd 17

4/10/12 15:09:07

THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITIS Berlin, Germany • October 18-20, 2012

Acknowledgements GOLD

Boehringer Ingelheim Binger Strasse 173 Ingelheim, 55216 Germany Contact: Dr Reinhard Malin Tel: (0) 6132.77.90815 Fax: (0) 6132.77.6601 Email: presse@boehringer-ingelheim.de Website: www.boehringer-ingelheim.com

Gilead Sciences Ltd 2 Roundwood Avenue, Stockley Park Uxbridge UB11 1AF United Kingdom

F. Hoffmann-La Roche Ltd F. Hoffmann-La Roche AG, Pharmaceuticals Division, Bldg 74/3O. Z02.18, CH-4070 Basel, Switzerland Contact: Gabriel Schnetzler Tel: +41 (0) 61.687.76.76 Fax: +41 (0) 61.688.23.48 Email: gabriel.schnetzler@roche.com Website: www.roche.com

Boehringer Ingelheim is a research-driven pharmaceutical group of companies dedicated to serving humankind by researching, developing, manufacturing and marketing pharmaceuticals that improve health and quality of life. Virology is one of seven R&D areas with Hepatitis C at the centre of interest. Our dedicated HCV treatment development programme, HCVersoTM, aims to deliver improved HCV treatment outcomes for patients, breaking down the barriers of current regimens and pursue new Interferon free treatment paradigm. As part of this program, Boehringer Ingelheim has advanced the clinical investigation of the 2nd wave protease inhibitor faldaprevir, and the combination of faldaprevir with the polymerase Inhibitor BI 207127 in an Interferon-free setting into Phase III. Gilead Sciences, a research-based biopharmaceutical company, discovers, develops and commercializes innovative medicines in areas of unmet need. Gilead’s focus includes liver disease, HIV/ AIDS and serious cardiovascular and respiratory conditions. With each new discovery and experimental drug candidate, we seek to improve the care of patients suffering from life-threatening diseases. Founded in 1987 in Foster City, California, Gilead employs some 4,000 people worldwide. As Gilead grows, so do our responsibilities as a corporate citizen and since 2003 our HIV access program has provided antivirals at substantially reduced prices in low- and middle-income countries. Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare, with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In the treatment of hepatitis C, Roche’s PEGASYS (peginterferon alfa-2a [40KD]) has proven efficacy supported by extensive clinical and real-world experience. Over the last decade PEGASYS has been studied in 11 pivotal clinical trials involving over 5700 patients, and more than 2 million patients have now been treated globally.

[ 18 ]

01-26-C-HEP-part 1.indd 18

4/10/12 15:09:08

THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITIS Berlin, Germany • October 18-20, 2012

Acknowledgements SILVER

Abbott 200 Abbott Park Road 06Mi, AP34-3 Abbott Park 60064-6189 Contact: Dirk van Eeden, director Public Affairs, Abbott International Tel & Fax: +1 847.938.8848 Email: dirk.vaneeden@abbott.com Website: www.abbott.com

Bristol-Myers Squibb GmbH & Co. KGaA Contact: Mr. Knut Hannibal-Teichmann Tel: +49 89.12142.474 Fax: +49 89.12142.464 Email: knut.hannibal-teichmann@bms. com

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs approximately 91,000 people and markets its products in more than 130 countries.

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. Around the world, our medicines are helping millions of patients in their fight against such diseases as cancer, cardiovascular disease, diabetes, hepatitis b, HIV, psychiatric disorders, and rheumatoid arthritis. For more information, please visit www. bms.com.

[ 19 ]

01-26-C-HEP-part 1.indd 19

4/10/12 15:09:09

THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITIS Berlin, Germany • October 18-20, 2012

Acknowledgements SPONSORS

Idenix Pharmaceuticals, Inc. 60 Hampshire Street Cambridge, MA 02139 Contact: Kelly Barry Tel: 617.995.9800 Fax: 617.995.9801 Email: barry.kelly@idenix.com Website: www.idenix.com

Novartis Pharma AG Forum 1, Novartis Campus, 4056 Basel Contact: Christian C. Roth Tel: +41 (0) 61.324.3122 Email: christian-claus.roth@novartis. com Website: www.novartis.com

Rottapharm | Madaus Colonia-Allee 15 Koln, 51067 Germany Contact: Cristina Lamberti Tel: +39 (0) 39.73.901 Fax: +39 (0) 39.73.90.372 Email: cristina.lamberti@rottapharm. com Website: www.rotta.com

Idenix Pharmaceuticals is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Our current primary research and development focus is on the treatment of patients infected with the hepatitis C virus (HCV). We are headquartered in Cambridge, Massachusetts. Our clinical development operations and drug discovery operations are conducted in Cambridge and the company’s European laboratory in Montpellier, France. The chemists and biologists leading the Idenix drug discovery team have substantial experience in the creation or modification of antiviral drugs. Idenix is able to rapidly discover compounds amenable to robust development and manufacturing processes. Building on our expertise in nucleoside chemistry and other small molecule chemistry and biology, we believe Idenix is well positioned to become a leader in antiviral pharmaceuticals. Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2011, the Group achieved net sales of USD 58.6 billion, while approximately USD 9.6 billion (USD 9.2 billion excluding impairment and amortization charges) was invested in R&D throughout the Group. Novartis Group companies employ approximately 126,000 full-time-equivalent associates and operate in more than 140 countries around the world. The Italian company Rottapharm|Madaus has a significant worldwide franchise and expertise in several medical fields, including hepatology/gastroenterology, with leading products such as Legalon and Legalon-SIL (silymarin and silibinin, sold in most Countries as anti-toxic treatments for liver pathologies ranging from NASH to acute mushroom poisoning). New R&D developments in the same area will further strengthen the company’s relationship with Hepatologists over the next few years. In particular, Silibinin has been granted the orphan drug designation from EMA and FDA for the prevention of recurrent hepatitis C in liver transplant recipients.

[ 20 ]

01-26-C-HEP-part 1.indd 20

4/10/12 15:09:11

THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITIS Berlin, Germany • October 18-20, 2012

EXHIBITION FOORPLAN

hall

6 POSTERS

EXHIBITION

REGISTRATION

COMPANY

MAIN ENTRANCE

STAND

Bristol-Myers Squibb

Merck Sharp & Dohme (MSD)

Rottapharm | Madaus

[ 21 ]

01-26-C-HEP-part 1.indd 21

4/10/12 15:09:16

THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITIS Berlin, Germany â&#x20AC;˘ October 18-20, 2012

PARTNERS Event Partners

The American Conference for the Treatment of HIV (ACTHIV) May 10-12, 2012 Denver, CO, USA

6th Conference of the Union Europe Region July 4-6, 2012 UK, London

E-AHPBA congress December 12-13, 2012 UK, London

Prague Hepatology Meeting 2012 September 20-22, 2012 Prague, Czech Republic

International Liver Cancer Association (ILCA) September 14-16, 2012 Berlin, Germany

Media Partners

[ 22 ]

01-26-C-HEP-part 1.indd 22

4/10/12 15:09:19

THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITIS Berlin, Germany • October 18-20, 2012

Endorsements

[ 23 ]

01-26-C-HEP-part 1.indd 23

4/10/12 15:09:20

THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITIS Berlin, Germany • October 18-20, 2012

GENERAL INFORMATION Congress Venue

Leonardo Royal Hotel Berlin Otto-Braun-Strasse 90 D-10249, Berlin, Germany Tel.: +49 (0) 30-755 430 0 Fax: +49 (0) 30-755 430 810 Email: info.royalberlin@leonardo-hotels.com Website: www.leonardo-hotels.com/Royal_Berlin_Hotel

Language

English is the official language of the Congress.

Registration and Hospitality Desk

The Registration Desk will operate during the following hours: Thursday, October 18, 2012

11:00-20:00

Friday, October 19, 2012

08:00-17:30

Saturday, October 20, 2012

08:00-12:40

Congress Kit and Name Tag

Name tags are included in your personal Congress Kit. Please wear your name tag during all sessions and social events. Key colors for name tags: C-HEP

C-HEP

2ND WORLD CONGRESS ON

CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITIS

Berlin, Germany • October 18-20, 2012

Blue: Participants

Orange: Faculty

Certificate of Attendance

Your Certificate of Attendance is included in your personal Congress Kit.

C-Hep Feedback Form

Please note that you have a C-Hep-CME Feedback Form in your Congress Kit. We would greatly appreciate hearing your comments. Once completed, this form may be handed in to the Registration Desk.

List of Participants

A list of pre-registered participants is displayed on the notice board. Please correct or add your name and address wherever necessary.

Internet and Email

Free Internet and email facilities will be available during Congress hours.

Refreshments

Coffee and tea will be served during the coffee breaks between sessions, as specified in the Timetable.

Lunches

A buffet lunch will be served for participants of the Congress on Friday, October 19, 2012 12:15-13:00. Please present your name tag at the entrance.

[ 24 ]

01-26-C-HEP-part 1.indd 24

4/10/12 15:09:23

THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITIS Berlin, Germany • October 18-20, 2012

GENERAL INFORMATION Speakers’ Preview Room

Speakers are invited to visit the Speakers’ Preview Room prior to their lecture and upload their presentation(s). Speakers should bring their slide presentations to be uploaded for their sessions no later than one break prior to the session in which they are scheduled. The Speakers’ Preview Room will be open during Congress hours as follows: Thursday, October 18, 2012

11:30-20:30

Friday, October 19, 2012

08:00-17:30

Saturday, October 20, 2012

07:30-12:40

Poster Presentation

Poster presenters should plan to be beside their posters during the designated coffee breaks, as specified in the program. Please see the Congress Secretariat for board allocation at the Congress. Posters should be mounted on Thursday, October 18, 2012 at 14:00-17:30 and removed by 12:45 on Saturday, October 20, 2012. The Organizing Committee is not responsible for posters that are not removed on time. Poster presentation times are as follows: Thursday, October 18, 2012

17:30-20:30

Friday, October 19, 2012

09:00-17:30

Saturday, October 20, 2012

08:30-12:45

Exhibition Hours Thursday, October 18, 2012

14:00-20:30

Friday, October 19, 2012

10:30-17:30

Saturday, October 20, 2012

10:00-12:45

Safety and Security

Please do not leave your personal belongings, bags or suitcases unattended at anytime.

Liability

The Congress Secretariat and Organizers cannot accept liability for personal accidents, nor loss of or damage to private property of participants, either during or directly arising from the 2nd World Congress on Controversies in the Management of Viral Hepatitis (C-Hep). Participants should make their own arrangements with respect to health and travel insurance.

Congress Secretariat

[ 25 ]

01-26-C-HEP-part 1.indd 25

4/10/12 15:09:25

One liver. One life.

One VIREAD.

First-line treatment for chronic hepatitis B (CHB) in adults with compensated liver disease and decompensated liver disease1

Maximising outcomes Viread® 245 mg film-coated tablets Active substance: tenofovir disoproxil (as fumarate). Composition: Each Viread film-coated tablet contains 245 mg of tenofovir disoproxil (as fumarate). Excipients: core: croscarmellose sodium, lactose monohydrate, magnesium stearate (E572), microcrystalline cellulose (E460), pregelatinised starch (gluten free). Coating: glycerol triacetate (E1518), hypromellose (E464), indigo carmine aluminium lake (E132). lactose monohydrate, titanium dioxide (E171). Therapeutic indications: HIV-1 infection: in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected adults. Hepatitis B infection: for the treatment of chronic hepatitis B in adults with compensated liver disease (with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels

and histological evidence of active inflammation and/or fibrosis) or with decompensated liver disease. Contraindications: Hypersensitivity to the active substance or to any of the excipients. Warning: contains lactose monohydrate. Undesirable effects: Very common (≥1/10): hypophosphatemia, dizziness, diarrhoea, vomiting, nausea, rash, asthenia. Common (≥1/100, <1/10): headache, abdominal pain, abdominal distension, flatulence, increased transaminases, fatigue. Uncommon (≥1/1,000, <1/100): hypokalemia, pancreatitis, rhabdomyolysis, muscular weakness, increased creatinine. Rare (≥1/10,000, <1/1,000): lactic acidosis, hepatic steatosis, hepatitis, angioedema, osteomalacia, myopathy, acute renal failure, renal failure, acute tubular necrosis, proximal

renal tubulopathy (including Fanconi syndrome), nephritis (including acute interstitial nephritis), nephrogenic diabetes insipidus. Other possible side effects: hypertriglyceridemia, hypercholesterolemia, insulin resistance, hyperglycemia, hyperlactataemia, lipodystrophy, immune reactivation syndrome, osteonecrosis, hepatomegaly. Pharmaceutical form and pack sizes: Packs containing 30 and 3 x 30 film-coated tablets. Medicinal product subject to medical prescription. Information as of: January 2012. Marketing authorisation holder: GILEAD Sciences International Ltd., Cambridge, CB21 6GT, UK. Representative in Germany: Gilead Sciences GmbH, 82152 Martinsried b. Munich.

Reference: 1. VIREAD, Summary of Product Characteristics. January 2012. VIR/IHQ/12-09//1199 Date of preparation: September 2012

GIVI0041_Hep-C-Advert_AW.indd 1 01-26-C-HEP-part 1.indd 26

18/09/2012 11:53 4/10/12 15:09:28

C-HEP THE 2ND WORLD CONGRESS ON

CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITIS

Berlin, Germany • October 18-20, 2012

SCIENTIFIC PROGRAM

www.comtecmed.com/chep • chep@comtecmed.com

27-34-C-HEP-part 2.indd 1

4/10/12 14:58:21

THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITIS Berlin, Germany • October 18-20, 2012

NOTES

[ 28 ]

27-34-C-HEP-part 2.indd 2

4/10/12 14:58:22

THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITIS Berlin, Germany • October 18-20, 2012

scientific program Thursday, October 18, 2012

[ HALL A ] 14:00-16:00 PLENARY SESSION 1 Hepatitis C – Addressing the Challenge

Moderators: Jürgen Rockstroh, Germany; Jonathan M. Schapiro, Israel 14:00-14:05

Chairpersons Conference Welcome Address

14:05-14:30 14:30-14:35

HCV in 2020: Any cases left? Rafael Esteban, Spain Discussion

14:35-15:00 15:00-15:05

HCV vaccine: where do we stand? Ulrich Spengler, Germany Discussion

Interferon-free HCV therapy: Are we getting there? 15:05-15:25 No: Graham Foster, UK 15:25-15:45 Yes: Heiner Wedemeyer, Germany 15:45-16:00 Discussion

16:00-17:30 Pipeline Showcase New Drugs on the Horizon

Moderator: Jonathan M. Schapiro, Israel 16:00-16:05 Introduction 16:05-16:20

Strategies towards cure of HCV infection: a personalized approach Heiner Wedemeyer, Germany Presentation supported by BMS

16:20-16:35

Combination DAA Therapy for Hepatitis C Douglas Mayers, USA Presentation supported by Idenix

16:35-16:50

Host targeting therapies for the treatment of Hepatitis C Claudio Avila, Switzerland Presentation supported by Novartis

16:50-17:05

The ANNAPURNA study: Evaluating the Combination of Setrobuvir, Danoprevir/r and Ribavirin With or Without Mericitabine in Patients With Chronic Hepatitis C Eckart Schott, Germany Presentation Supported by Roche

17:05-17:20

Silibinin dihydrogensuccinate for the prevention of hepatitis C recurrence after liver transplantation and treatment of non-responders to anti-HCV therapy Lucio Rovati, Italy Presentation Supported by Rottapharm | Madaus

17:20-17:30

Panel Discussion

17:30-18:00 Coffee Break and Poster Exhibition

[ 29 ]

27-34-C-HEP-part 2.indd 3

4/10/12 14:58:23

THE 2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITIS Berlin, Germany â&#x20AC;˘ October 18-20, 2012

scientific program Thursday, October 18, 2012

[ HALL A ] 18:00-19:15 Satellite Symposium

JANSSEN PHARMACEUTICALS

DAAs: RISING STANDARDS IN PATIENT CARE

18:00-18:05 Welcome and introduction: Thomas Berg, Germany 18:05-18:25 Practical recommendations in the era of DAAs: Vlad Ratziu, France 18:25-18:45 Managing DAA treatment in HIV-HCV co-infected patients: Massimo Puoti, Italy 18:45-19:05 Understanding our patients: challenging clinical cases: Marina Berenguer, Spain 19:05-19:15 Summary and key learnings: Thomas Berg, Germany

19:15-20:30 Welcome Reception